The panel has ruled that the patents covering the active ingredient and a pharmaceutical composition thereof are valid, enforceable and infringed by the generic manufacturer’s product. In the same decision, the Court also ruled that a third patent covering the use in the treatment of inflammation was invalid.
The decision prohibits Teva from launching a competitor drug in the US until May 2014. Either party may request a rehearing by the Court of Appeals or a review by the US Supreme Court.